TOKYO, Jun 17 (Pulse News Wire) – RIBOMIC Inc. (4591.T) received designation for its achondroplasia treatment candidate RBM-007 (umedaptanib pegol) as a rare disease drug from the Ministry of Health, Labour and Welfare effective April 25, 2025.
Under this program, RIBOMIC can apply for grants up to half of research expenses within three years from approval until manufacturing and marketing application submission. Additionally, the company can benefit from reduced consultation fees during clinical trials and tax deductions for eligible trial costs. In the fiscal year ending March 2026, RIBOMIC reported capital of ¥872 million and a net loss of 1,145.
Revenue increased to 1,547 million yen compared to the previous year due to continued development of its DDS technology. Research and development expenses rose to 1,038 million yen primarily due to Phase 3 clinical trial preparations for RBM-007. For the fiscal year ending March 2027, RIBOMIC forecasts revenue of 1,547 million yen and expects to incur further research and development costs of 1,038 million yen for RBM-007's Phase 3 clinical trials.
The company plans to exercise the 19th warrant rights issue to raise additional funds.
🟡 Confidence: Standard AI-translated content.